Merck, Bristol-Myers Will Test Hepatitis C Regimen

Mon, 04/22/2013 - 9:19am

WHITEHOUSE STATION, N.J. (AP) — Merck and Bristol-Myers Squibb will run a mid-stage clinical trial of a drug regimen designed to treat the most common type of the hepatitis C virus.

The trial will study a combination of Bristol's drug daclatasvir, and Merck's MK-5172. Merck will run the trial in which patients with genotype 1 hepatitis C will be monitored. That is both the most common type of the virus and the toughest to treat.

Bristol-Myers is running late-stage trials of daclatasvir and MK-5172 is in mid-stage testing. Merck's hepatitis C drug Victrelis was approved in 2011.

Shares of Merck & Co. closed at $47.49 Friday and Bristol-Myers Squibb Co. shares finished at $41.15.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.